Breye Therapeutics Strengthens Management Team and Board

  • Industry veteran Dr. Peter Adamson, PhD appointed as Chief Scientific Officer
  • Dr. Gabriela Burian, MD appointed to the Board of Directors

Copenhagen, Denmark, 20 April 2023 Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the appointment of Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors.

Read more…